GLPwatch
Ozempic for Heart failure (HFpEF)
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) is not FDA-approved for treating heart failure with preserved ejection fraction (HFpEF). Research includes studies on its potential effects on cardiotoxicity and HFpEF, as well as safety analyses, but these findings are investigational.
AI summary of the sources below.
| Drug | Ozempic (semaglutide) |
|---|---|
| Condition | Heart failure (HFpEF) |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Ozempic is not FDA-approved for heart failure (hfpef); the research below reflects investigational or off-label study only.
Research on semaglutide for heart failure (hfpef) (50)
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
- Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
- Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
- Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.
- Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
- Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis.
- Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
- Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
- Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
- Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
- Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats.
- Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
- Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.
- Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
- Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
- Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway.
- Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
- Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
- Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome.
- Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA<sub>1c</sub> levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
- Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.